Endocrine Abstracts (2009) 20 P445

Effect of metformine treatment on serum paraoxonase and oxidative status in obese women

Semin Fenkci1, Nedim Karagenc2 & Fulya Akin3


1Department of Internal Medicine, School of Medicine, Pamukkale University, Denizli, Turkey; 2Department of Medical Biology, School of Medicine, Pamukkale University, Denizli, Turkey; 3Department of Endocrinology and Metabolism, School of Medicine, Pamukkale University, Denizli, Turkey.


Objective: To evaluate the effects of metformine newly using in clinical practice to ameliorate insulin resistance on paraoxonase activity and oxidative stress in obese insulin resistant women.

Materials and methods: Sixty-seven obese (BMI≥30 kg/m2) women were enrolled into this study. Serum fasting (F.Glc) and postprandial glucose (P.Glc), insulin, uric acid (UA), paraoxonase (PON1), Arylesterase (AET), malondialdehyde (MDA), cupper-MDA (Cu-MDA) levels and lipid fractions were measured at the commencement and ending of the study. Homeostasis model assessment (HOMA-R) was used to estimate insulin resistance. HOMA-R ≥ 2.7 levels were accepted as positive insulin resistance. According to this proposal, insulin resistant (IR+) 32 women were defined as Group I and no insulin resistant (IR−) 35 as Group II. Cases in Group I were managed by diet + exercise + metformine (1700 mg/d), cases in Group II were only treated by diet + exercise for 6-month interval. Intra and inter alterations of all parameters were statistically calculated.

Results: Basal PON1, MDA, Cu-MDA and HOMA-R values were considerably higher in Group II than those in Group II. Reduced PON1/AET ratio, HOMA-R, HDL and PON1 values were observed in Group I. The increases in AET/HDL and Cu-MDA were significant. While increases in LDL, Cu-MDA, AET/HDL and HOMA-R values were observed, HDL level reduced in Group II. Decreases in HOMA-R values were further in Group I than in Group II. But increases in Cu-MDA levels were significantly higher in Group II compared to those in Group I.

Conclusions: We thought that metformine treatment with intensive life-style changing is appropriate management in obese, insulin resistant women who have increased propensity for the development of Type 2 DM.

Article tools

My recent searches

No recent searches.